Header Logo

Connection

RIMA M SALIBA to CD52 Antigen

Back to Details
This is a "connection" page, showing publications RIMA M SALIBA has written about CD52 Antigen.
RIMA M SALIBA
Connection Strength
0.015
CD52 Antigen
  1. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant. 2004 Apr; 33(8):833-7.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.